Plain English Summary
Background and study aims
Hemodialysis is a process of purifying the blood of a person whose kidneys are not working normally. A condition called protein-energy wasting, where the body has decreased stores of protein and fat, is common in patients undergoing hemodialysis. Studies have looked at the benefits of oral nutritional supplements, resistance exercise (e.g., weight training) and aerobic exercise (e.g., cycling) on nutrition and physical function, but it is not known what kind of treatment is best for patients. The aim of this study is to compare the effect of oral nutritional supplementation plus resistance exercise, oral nutritional supplementation plus aerobic exercise, and oral nutritional supplementation alone.
Who can participate?
Patients aged 18 to 45 undergoing hemodialysis
What does the study involve?
Participants are randomly allocated to receive one of three treatments two times per week for 12 weeks: either oral nutritional supplement plus resistance exercise, oral nutritional supplement plus aerobic exercise, or oral nutritional supplement alone. At the end of the study participants’ body measurements, blood test results, physical function and quality of life are assessed.
What are the possible benefits and risks of participating?
It has been shown that exercise and oral nutritional supplements are safe and beneficial. Low blood pressure and symptoms such as diarrhoea and nausea have been associated with oral nutritional supplements, but there is a lack of evidence supporting this.
Where is the study run from?
Hospital General de México, Dr Eduardo Liceaga (Mexico)
When is the study starting and how long is it expected to run for?
January 2016 to September 2017
Who is funding the study?
Hospital General de México, Dr Eduardo Liceaga (Mexico)
Who is the main contact?
1. Dr Lucía Monserrat Pérez
2. Miss Geovana Martin
Trial website
Contact information
Type
Scientific
Primary contact
Dr Lucía Monserrat Pérez
ORCID ID
http://orcid.org/0000-0002-9281-9202
Contact details
Dr. Balmis 148
Cuauhtémoc
Doctores
México City
06726
Mexico
Type
Public
Additional contact
Miss Geovana Martin
ORCID ID
http://orcid.org/0000-0003-3583-6126
Contact details
Dr. Balmis 148
Cuauhtémoc
Doctores
México City
06726
Mexico
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
DI/16/105-B-04-128
Study information
Scientific title
A prospective randomized trial, Aerobic Versus ANaerobic exercise and oral nuTritional supplEmentation in nutritional status and physical function of adults HEMOdialysis Patients: the AVANTE-HEMO study
Acronym
AVANTE-HEMO
Study hypothesis
Hemodialysis (HD) patients who perform resistance exercise (RE) + receive oral nutritional supplementation (ONS) will have better parameters of nutritional status and physical function than patients of the aerobic plus oral nutritional supplementation group and oral nutritional supplementation group.
Ethics approval
Hospital General de México, Dr. Eduardo Liceaga ethics committee, 28/09/2016, ref: DI/16/105-B-04-128
Study design
Parallel single-centre randomised controlled trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Not available in web format, please use contact details to request a participant information sheet
Condition
Hemodialysis
Intervention
Method of randomization: A blocked design will be used, using an online statistical computing web programming (www.randomizer.org) to generate the randomization schedule, 14 sets of 3 unique numbers per set range from 1 to 3 (representing the three treatment arms).
Control arm
During the HD sessions, patients receive a can of a specialized oral nutritional supplement for maintenance dialysis patients that consists of 480 kcal, 20 g protein and 20 g lipids (Enterex RNL, Pisa Laboratories). Enterex RNL contains omega-3 and omega-6 fatty acids, maltodextrin and sucralose.
Aerobic exercise arm
Patients of this group receive the same specialized oral nutritional supplement during the HD session, half of the a can is administered during the first hour of the HD session and the other half after the AE routine. Aerobic exercise consists of pedaling a stationary bike for the first two hours of the HD session, the optimal exercise time is established during the first session, then is gradually increased to reach 20-30 minutes. The scale of perceived exertion Borg (6-20) is used to establish the intensity of the exercise (moderate intensity, 12-13).
Resistance exercise arm
Patients of this group receive the same specialized oral nutritional supplement during the HD session, half of the a can is administered during the first hour of the HD session and the other half after the RE routine. Patients are trained for three months according to an adaptation to the program “Exercise: A Guide for People on Dialysis”. Four types of resistance exercise are performed during the second hour of the HD session (four sets of 20 repetitions for 40 min). TheraBand Latex Resistance Bands are used to individualize the exercise. The scale of perceived exertion Borg (6-20) is used to establish the intensity of the exercise (moderate intensity, 12-13)
Frequency and duration of treatment: Two times per week for 12 weeks (40 minutes of resistance exercise and 30 minutes of aerobic exercise)
Follow-up: 12 weeks
Intervention type
Mixed
Phase
Drug names
Primary outcome measures
Measured at baseline and 3 months:
1. Weight: The weight reached by the patient at the end of a session which has removed the maximum fluid without inducing hypotension (seca 676 wheelchair scale, wireless)
2. Body mass index: body mass divided by the square of the body height
3. Anthropometric measurements: skinfold thickness (biceps, triceps, subescapular, supra-iliac) using a Lange skin fold caliper to estimate:
3.1. Fat mass percentage: calculated using Siri´s (1956) equation = (4.95/density)-4.50*100
3.2. Mid-upper arm circumference: measured at the mid-point between the tip of the shoulder ant the tip of the elbow (olecranon process and the acromium)
3.3. Mid arm muscle circumference = mid arm circumference – (π x triceps skinfold thickness)
3.4. Bone-free arms muscle area: males = [(midarm circumference (cm) - π x triceps (cm)]2/4 π) - 10; females = [(midarm circumference (cm) - π x triceps (cm)]2/4 π) - 6.5
4. Handgrip strength, measured using hand dynamometry (Smedley III, Takei Scientific Instruments, Niigata City, Japan)
5. Serum albumin, measured using the bromocresol purple albumin assay
6. Physical function, measured using the six-minute walk test according to the American Thoracic Society Guidelines, Time Up and Go Test (Podsiadlo, D et al. J Am Geriatr Soc, 1191;39:142-148), five times sit to stand test
7. Bioelectrical impedance analysis (resistance, reactance and phase angle), measured using conventional impedance (single frequency; Quantum System, RJL Systems, Clinton Township, MI, USA)
Secondary outcome measures
Measured at baseline and 3 months:
1. Quality of life, measured using the Kidney Disease Quality of Life Short Form (KDQOF-SF)
2. C Reactive Protein, measured using the nephelometric assay
Overall trial start date
01/01/2016
Overall trial end date
01/09/2017
Reason abandoned
Eligibility
Participant inclusion criteria
1. Regular HD two or more times a week
2. Signed informed consent
3. Any gender
4. Age >18 to <45 years
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
40
Participant exclusion criteria
1. Patients with an amputation
2. Hospitalization in the last 3 months
3. Unsatisfactory attendance at HD sessions
4. Pregnancy
5. Excessive pallor
6. Severe dyspnea
7. Femoral fistula
8. Arrhythmias
9. Precordial pain
10. Orthopedic or neurological compromises or cognitive alterations affecting their participation in the study
Recruitment start date
01/11/2016
Recruitment end date
31/01/2017
Locations
Countries of recruitment
Mexico
Trial participating centre
Hospital General de México, Dr Eduardo Liceaga
Dr. Balmis 148
Cuauhtémoc
Doctores
Ciudad de México, D.F.
06726
Mexico
Sponsor information
Organisation
Hospital General de México, Dr Eduardo Liceaga
Sponsor details
Dr. Balmis 148
Cuauhtémoc
Doctores
México City
06726
Mexico
Sponsor type
Hospital/treatment centre
Website
Funders
Funder type
Hospital/treatment centre
Funder name
Hospital General de México, Dr Eduardo Liceaga
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
To be confirmed at a later date
Intention to publish date
01/09/2018
Participant level data
Not provided at time of registration
Results - basic reporting
Publication summary